20000332 1-7

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/485 — A1

(11) International Publication Number: **WO 99/32119**

(43) International Publication Date: 1 July 1999 (01.07.99)

(21) International Application Number: PCT/US98/27257

(22) International Filing Date: 22 December 1998 (22.12.98)

(30) Priority Data:
60/068,480 22 December 1997 (22.12.97) US

(71) Applicant *(for all designated States except US)*: EURO-CELTIQUE, S.A. [LU/LU]; 122, boulevard de la Petrusse, L-2330 Luxembourg (LU).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: KAIKO, Robert, F. [US/US]; 10 Norfield Woods Road, Weston, CT 06883 (US). COLUCCI, Robert, D. [US/US]; 28 Clearview Drive, Newtown, CT 06482 (US).

(74) Agents: DAVIDSON, Clifford, M. et al.; Davidson, Davidson & Kappel, LLC, 15th floor, 1140 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: OPIOID AGONIST/ANTAGONIST COMBINATIONS

(57) Abstract

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative "aversive" experience in physically dependent addicts (e.g., precipitated abstinence syndrome).